West Bancorporation Inc. Has $261,000 Stock Position in Boston Scientific Co. (NYSE:BSX)

West Bancorporation Inc. lessened its stake in shares of Boston Scientific Co. (NYSE:BSX) by 3.7% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 2,921 shares of the medical equipment provider’s stock after selling 112 shares during the quarter. West Bancorporation Inc.’s holdings in Boston Scientific were worth $261,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the company. Values First Advisors Inc. purchased a new stake in shares of Boston Scientific in the third quarter worth approximately $28,000. Dunhill Financial LLC boosted its position in Boston Scientific by 86.4% during the third quarter. Dunhill Financial LLC now owns 328 shares of the medical equipment provider’s stock valued at $28,000 after purchasing an additional 152 shares during the last quarter. Global Wealth Strategies & Associates grew its stake in Boston Scientific by 423.7% in the fourth quarter. Global Wealth Strategies & Associates now owns 309 shares of the medical equipment provider’s stock valued at $28,000 after purchasing an additional 250 shares in the last quarter. West Oak Capital LLC acquired a new position in Boston Scientific in the 4th quarter worth about $29,000. Finally, E Fund Management Hong Kong Co. Ltd. acquired a new stake in shares of Boston Scientific during the 3rd quarter valued at about $30,000. 89.07% of the stock is owned by hedge funds and other institutional investors.

Boston Scientific Stock Down 0.6 %

BSX opened at $102.40 on Friday. Boston Scientific Co. has a fifty-two week low of $62.63 and a fifty-two week high of $104.25. The company has a market capitalization of $150.92 billion, a P/E ratio of 84.63, a P/E/G ratio of 2.69 and a beta of 0.80. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.48 and a quick ratio of 1.02. The firm’s fifty day moving average price is $93.22 and its two-hundred day moving average price is $86.04.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. Needham & Company LLC restated a “hold” rating on shares of Boston Scientific in a report on Wednesday, November 27th. Bank of America boosted their price target on Boston Scientific from $90.00 to $100.00 and gave the stock a “buy” rating in a research report on Tuesday, October 22nd. Raymond James increased their price objective on Boston Scientific from $101.00 to $119.00 and gave the company a “strong-buy” rating in a report on Friday. StockNews.com upgraded Boston Scientific from a “hold” rating to a “buy” rating in a report on Wednesday. Finally, BTIG Research lifted their price target on shares of Boston Scientific from $84.00 to $93.00 and gave the company a “buy” rating in a research report on Monday, October 14th. Two equities research analysts have rated the stock with a hold rating, twenty-one have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $98.35.

Insider Activity at Boston Scientific

In other Boston Scientific news, EVP John Bradley Sorenson sold 4,119 shares of the company’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $90.02, for a total value of $370,792.38. Following the sale, the executive vice president now directly owns 35,319 shares in the company, valued at $3,179,416.38. This represents a 10.44 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Arthur C. Butcher sold 14,010 shares of the business’s stock in a transaction on Monday, November 25th. The shares were sold at an average price of $89.27, for a total transaction of $1,250,672.70. Following the completion of the sale, the executive vice president now owns 978 shares in the company, valued at $87,306.06. This represents a 93.47 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 29,989 shares of company stock valued at $2,702,261 over the last quarter. 0.50% of the stock is owned by company insiders.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.